Interim Report for the period October – December 2022

The US FDA approved Leqembi™ under the accelerated approval pathway for the treatment of Alzheimer's disease Events during the fourth quarter 2022 · Detailed and positive lecanemab data from the Phase 3 study, Clarity AD, were presented by Eisai at the CTAD Alzheimer Congress. The results were simultaneously published in the New England Journal of Medicine · BioArctic started the two new projects, PD-BT2238, a selective antibody against soluble alpha-synuclein aggregates, and GD-BT6822, an enzyme replacement therapy for Gaucher’s disease. Both projects are combined with the